The United States Food and Drug Administration today, in a letter to healthcare providers, reversed its restrictions on the use of paclitaxel-based therapies in peripheral vascular interventions (PVIs ...
Which Patients With Microscopic Disease and Rhabdomyosarcoma Experience Relapse After Therapy? A Report From the Soft Tissue Sarcoma Committee of the Children’s Oncology Group PURPOSE: To create a ...
Final survival results from the WSG ADAPT hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) chemotherapy trial demonstrated that weekly nanoparticle ...
LONDON, England—While it’s not clear sirolimus-based devices will ever overtake the old workhorse paclitaxel, data from several studies presented here at the 2025 Charing Cross International Symposium ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
A combination of chemotherapy and drugs that stimulate the immune system to combat cancer is increasingly used to control progression of the disease in patients. On the other hand, clinical studies ...
What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).
After more than four years of scientific review, the FDA is rolling back warnings over cardiovascular devices and implants coated with the drug paclitaxel, saying studies have shown they do not carry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results